SWX:ROGPharmaceuticals
Did New Long-term Vabysmo Data Just Shift Roche Holding's (SWX:ROG) Investment Narrative?
Roche recently presented new data from its AVONELLE-X and SALWEEN studies of Vabysmo at the Euretina Congress in Paris, highlighting the drug’s lasting efficacy and safety in treating neovascular age-related macular degeneration and polypoidal choroidal vasculopathy.
With nearly 80% of patients benefitting from extended dosing and significant vision improvements among difficult-to-treat cases, these outcomes reinforce Vabysmo’s importance in retinal disease management and support its...